LX-2020

N/A

Report date: 2024/03/28 13:04:35

Base Information

Drug NameLX-2020
Drug Alias NameLX-2020LX2020
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAVrh10 vector
Mechanisms of ActionPlakophilin-2 gene transference
TargetsPlakophilin-2
Therapy Area/IndicationsCardiomyopathies
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesStelios Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesLexeo Therapeutics IncLEXEO Therapeutics
Inactive CompaniesN/A
Active IndicationsCardiomyopathies
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A